| Title |
Safety and efficacy of vernakalant for acute cardioversion of atrial fibrillation: an update
|
|---|---|
| Published in |
Vascular Health and Risk Management, April 2013
|
| DOI | 10.2147/vhrm.s43720 |
| Pubmed ID | |
| Authors |
Yukiomi Tsuji, Dobromir Dobrev |
| Abstract |
Intravenous vernakalant has recently been approved in Europe as an atrial-selective antiarrhythmic drug for the conversion of recent-onset atrial fibrillation (AF). It inhibits atrial-selective K(+) currents (I(K,ACh) and I(Kur)) and causes rate-dependent atrial-predominant Na(+) channel block, with only a small inhibitory effect on the rapid delayed rectifier K(+) current (I(Kr)) in the ventricle. Due to its atrial-selective properties, vernakalant prolongs the effective refractory period of the atria with minimal effects on the ventricles, being associated with a low proarrhythmic risk for torsades de pointes arrhythmias. Five pivotal clinical trials consistently demonstrated that vernakalant rapidly terminates AF with stable maintenance of sinus rhythm for up to 24 hours. A head-to-head comparative trial showed that the 90-minute conversion rate of vernakalant was substantially higher than that of amiodarone. Initially, a longer-acting oral formulation of vernakalant was shown to be effective and safe in preventing AF recurrence after cardioversion in a Phase IIb study. However, the clinical studies testing oral vernakalant for maintenance of sinus rhythm after AF cardioversion were prematurely halted for undisclosed reasons. This review article provides an update on the safety and efficacy of intravenous vernakalant for the rapid cardioversion of AF. |
X Demographics
The data shown below were collected from the profiles of 4 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | 25% |
| Unknown | 3 | 75% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Practitioners (doctors, other healthcare professionals) | 2 | 50% |
| Members of the public | 2 | 50% |
Mendeley readers
The data shown below were compiled from readership statistics for 52 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 1 | 2% |
| Spain | 1 | 2% |
| United States | 1 | 2% |
| Greece | 1 | 2% |
| Unknown | 48 | 92% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 14 | 27% |
| Other | 6 | 12% |
| Student > Bachelor | 5 | 10% |
| Student > Ph. D. Student | 5 | 10% |
| Student > Postgraduate | 5 | 10% |
| Other | 10 | 19% |
| Unknown | 7 | 13% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 24 | 46% |
| Agricultural and Biological Sciences | 5 | 10% |
| Nursing and Health Professions | 4 | 8% |
| Pharmacology, Toxicology and Pharmaceutical Science | 4 | 8% |
| Engineering | 3 | 6% |
| Other | 5 | 10% |
| Unknown | 7 | 13% |
Attention Score in Context
This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 19 May 2013.
All research outputs
#15,305,492
of 25,584,565 outputs
Outputs from Vascular Health and Risk Management
#436
of 785 outputs
Outputs of similar age
#119,111
of 213,424 outputs
Outputs of similar age from Vascular Health and Risk Management
#9
of 12 outputs
Altmetric has tracked 25,584,565 research outputs across all sources so far. This one is in the 38th percentile – i.e., 38% of other outputs scored the same or lower than it.
So far Altmetric has tracked 785 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 9.5. This one is in the 41st percentile – i.e., 41% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 213,424 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 42nd percentile – i.e., 42% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 12 others from the same source and published within six weeks on either side of this one. This one is in the 25th percentile – i.e., 25% of its contemporaries scored the same or lower than it.